AICAR gets sold next to BPC-157 and TB-500 as another injectable research peptide for endurance and fat loss. It isn’t a peptide at all: it’s a ribonucleoside, a nucleotide-type molecule built on a purine base, with no amino acid chain in it anywhere[1]. That alone would just be a labeling error, except the mislabeling hides something stranger underneath it.
AICAR has been studied in people, including 4,043 CABG surgery patients in five trials pooled in a 1997 meta-analysis[2]. A separate, later trial, RED-CABG, did not reduce its 28-day composite of death, nonfatal stroke or severe left ventricular dysfunction[3]. Human research also includes acute metabolism experiments and a small leukemia study; cardiac surgery is not its entire clinical record[4][5].
What AICAR’s human trials tested
Clinically, AICAR is called acadesine. Its human research includes coronary artery bypass graft (CABG) surgery, acute muscle glucose-uptake experiments in healthy men, and an open-label phase I/II study in 24 patients with relapsed or refractory chronic lymphocytic leukemia (CLL)[4][5]. These studies address different populations and endpoints, not interchangeable measures of benefit.
- The pooled evidence base. A meta-analysis combining individual patient data from five randomized, double-blind, placebo-controlled trials across 81 centers in the US, Canada and Europe covered 4,043 CABG patients, split roughly evenly between acadesine and placebo[2].
- The verdict that mattered most. The later RED-CABG trial was a separate randomized study at 300 sites in 7 countries, not one of the five trials included in the 1997 meta-analysis[3].
Bottom line: RED-CABG was stopped early, after a prespecified futility analysis, when the data made clear it had almost no chance of showing a benefit. The primary outcome, death, nonfatal stroke, or severe heart failure needing mechanical support, occurred in 5.0% of the placebo group and 5.1% of the acadesine group[3].
The earlier pooled analysis reported lower rates of perioperative myocardial infarction and early cardiac death[2]. RED-CABG subsequently randomized 3,080 participants before stopping for futility; it did not show a benefit on its primary composite endpoint[3]. An earlier positive pooled result and a later negative trial should not be collapsed into the claim that every human study failed.
The cardiac results apply to the surgery populations and endpoints studied. They do not establish an endurance benefit, but they also do not describe all human AICAR research.
The mechanism: an AMP mimetic wearing a peptide’s reputation
AICAR’s chemistry is well mapped, and none of it involves amino acids.
What’s established: AICAR is one of the most widely used pharmacological activators of AMP-activated protein kinase (AMPK), the enzyme that functions as the cell’s energy gauge[1]. In rat hindlimb muscle, perfusing AICAR activates AMPK, shuts down acetyl-CoA carboxylase, and drops malonyl-CoA levels. The downstream effect in that experiment was a 2.8-fold jump in fatty acid oxidation over 45 minutes, plus a measurable rise in glucose uptake[6].
What’s overstated: a lot of popular explainers describe AICAR as simply “turning on AMPK,” full stop. A systematic review found that a growing body of work traces many of AICAR’s cellular effects, spanning metabolism, hypoxia, exercise, nucleotide synthesis and cancer biology, to pathways that don’t run through AMPK at all[1]. The compound was the field’s default tool for studying AMPK for two decades, and the same review that documents its everyday use is the one warning other researchers not to trust it as a clean AMPK probe anymore.
That second point matters more than it sounds. If researchers who have spent two decades studying this molecule in cell culture and rodent tissue still can’t cleanly separate its AMPK effects from its non-AMPK effects, a marketing claim that it will “activate your metabolism” in a human body is not a simplification. It’s a guess dressed up as a mechanism.
The dosing nobody selling AICAR mentions
The “exercise in a pill” reputation traces to one mouse study, and the dosing in that study looks nothing like what research-chemical vendors sell.
44% increase in treadmill endurance, sedentary mice, 4 weeks of AICAR alone, no exercise PMID 18674809
Narkar and colleagues gave untrained, sedentary mice daily AICAR injections for four weeks and found that even without any treadmill training, the treated mice ran 44% longer before exhaustion than untreated controls, alongside changes in muscle metabolic gene expression[7]. This animal experiment does not establish a human endurance regimen.
Compare that to how the drug was dosed in people:
Different AICAR research settings
| Setting | Population | Regimen | Outcome measured |
|---|---|---|---|
| Mouse endurance study | Sedentary, untrained mice | Daily injection for 4 weeks | Treadmill run time to exhaustion |
| Human cardiac trials | CABG surgery patients | Single intravenous infusion around surgery | Death, MI, stroke, heart failure |
| Human metabolism study (2007) | Healthy men | Acute intravenous infusion | Muscle 2-deoxyglucose uptake and whole-body glucose disposal |
| Human phase I/II CLL study (2013) | 24 patients with relapsed or refractory CLL | Monitored intravenous administration; single or repeated infusions | Safety, tolerability and exploratory disease observations |
Selected studies, not a complete inventory. Acute metabolic and oncology studies do not establish athletic benefit.
In the cardiac-surgery setting, acadesine was measured in blood plasma during intravenous infusion to patients undergoing coronary artery bypass graft surgery, a hospital dosing pattern distinct from the sustained daily injections used in the rodent endurance studies[8]. A separate 2007 human study measured acute muscle 2-deoxyglucose uptake and whole-body glucose disposal during AICAR infusion[4]. The CLL study used monitored intravenous administration, including repeated infusions in a small subgroup[5]. None of these endpoints establishes improved athletic endurance or long-term fat loss.
Side effects, and a ban built on mouse data
Here the honest answer splits into two very different evidence bases.
In the cardiac trials, pooled short-term adverse-event rates were similar to placebo apart from a transient uric-acid rise[2]. This cannot establish safety in other settings. The CLL study reported renal impairment and clinically significant transient infusion-related hypotension, among other events[5]. A negative efficacy result in CABG patients is not a general safety verdict.
In competitive sport, AICAR carries a different weight entirely. The World Anti-Doping Agency added AICAR to its Prohibited List in 2009, on the strength of the 2008 mouse endurance data and reports of illicitly distributed AICAR circulating among athletes, not any demonstrated performance effect in trained humans[9]. It went on the list alongside GW501516 (Cardarine to anyone who’s spent time in a supplement forum), a PPARδ agonist tested in the same mouse experiments. Both drugs earned a sport-wide ban off the back of rodent data, years before either one had a published human performance trial to its name.
The studies cited here do not establish the safety of chronic, unsupervised AICAR use. Their participants, monitoring and regimens differ from research-chemical self-use. A WADA prohibition is also not a clinical safety approval.
Where AICAR sits next to metformin
AICAR is not the only drug that works partly by nudging the AMPK pathway. Metformin does too, and the contrast is instructive.
Metformin, the most widely prescribed AMPK-adjacent drug on the planet, has decades of outcome data behind it. In the UK Prospective Diabetes Study’s 10-year post-trial follow-up, overweight type 2 diabetes patients originally assigned to metformin showed significant long-term reductions in myocardial infarction (33%) and death from any cause (27%), years after the active treatment phase had ended[10]. That isn’t a mechanism paper or a rodent study: it’s a decade of real patients living or dying at measurably different rates.
Human AICAR research does not validate performance claims for AICAR or for a peptide sold online. Cardiac outcomes, acute metabolic measurements and exploratory oncology observations answer different questions; none can simply be substituted for an endurance or fat-loss result[3][4][5].
What would settle the performance question
The relevant question is whether a study directly measures an athletic or body-composition outcome in the population making the claim.
The human studies cited here do not demonstrate improved endurance or sustained fat loss. The 2007 metabolic experiment measured acute glucose handling, not a training benefit[4]. The CLL study investigated safety and tolerability in previously treated patients, not performance in healthy athletes[5]. This is a limit of these sources, not proof that no other human study exists.
The same distinction matters when comparing AICAR with real peptides that still can’t clear this bar. Existing human research should be described accurately, then judged against the specific outcome being claimed. A failed cardiac endpoint is not proof that every human effect failed, and a metabolic observation is not proof of an athletic benefit.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
- AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review.. Cells, 2021.
- Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group.. JAMA, 1997.
- Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial.. JAMA, 2012.
- 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men.. Diabetes, 2007.
- Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study.. Cancer chemotherapy and pharmacology, 2013.
- AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle.. The American journal of physiology, 1997.
- AMPK and PPARdelta agonists are exercise mimetics.. Cell, 2008.
- Spectrophotometric determination of acadesine (AICA-riboside) in plasma using a diazotization coupling technique with N-(1-naphthyl)ethylenediamine.. Journal of biochemical and biophysical methods, 1994.
- Metabolic modulators of the exercise response: doping control analysis of an agonist of the peroxisome proliferator-activated receptor δ (GW501516) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR).. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2014.
- 10-year follow-up of intensive glucose control in type 2 diabetes.. The New England journal of medicine, 2008.



